Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
January 30, 2024 12:00 ET
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:28 ET
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens indication areas to...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:26 ET
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
November 17, 2023 08:00 ET
|
Serina Therapeutics, Inc.
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a...
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
November 06, 2023 07:45 ET
|
Revive Therapeutics Ltd.
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd....
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies
July 05, 2023 08:00 ET
|
F-star Therapeutics, Inc.
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, an invoX company (“F-star”), today announced that it has entered into a strategic discovery collaboration and licence agreement with...
Aridis Provides Corporate Update
March 31, 2023 19:00 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on...
AnaBios Boosts Discovery of Safer, More Effective Medicines With License From the University of Louisville
February 14, 2023 09:00 ET
|
AnaBios
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new drugs, today announced a technology transfer...
Genmab and Synaffix Enter into License Agreement for ADC Technology
January 04, 2022 09:00 ET
|
Genmab A/S
Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...
Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
September 16, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to...